Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Treatment Modalities for Esophageal Cancer
NCT04821843Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2002
- Primary completion
- Dec 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of nimotuzumab in esophageal cancer and esophagogastric junction cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall Survival at 5 years. Started Jan 2002; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NCT04821843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821843.